Quantcast

Latest Pyrrolidines Stories

2014-09-08 08:32:02

DENVER, Sept. 8, 2014 /PRNewswire/ -- Silvergate Pharmaceuticals, Inc. (www.Silvergatepharma.com), focused on the development and commercialization of innovative and safe medicines for children, today announced that the United States Food and Drug Administration (FDA) approved Epaned® (enalapril maleate Powder for Oral Solution) for the treatment of symptomatic heart failure and the treatment of asymptomatic left ventricular dysfunction (to decrease the rate of development of overt heart...

2014-09-08 08:29:26

--Phase 2a Trial is First to Use Crowdsourcing for Protocol Design and Telemonitoring for Patient Data Collection-- NEW YORK, Sept. 8, 2014 /PRNewswire/ -- Transparency Life Sciences, LLC (TLS), the world's first clinical-stage drug development company based on open innovation, today announced that it has received a Small Business Innovation Research (SBIR) program grant to fund a Phase 2a proof-of-concept study testing the utility of the ACE inhibitor lisinopril as an adjunctive...

2014-08-30 12:20:58

-- LCZ696 mortality benefit exceeded what was achieved with enalapril, an ACE-inhibitor, when replacing enalapril combined with current treatment regimen for HF-REF1 -- Study showed significantly more HF-REF patients on LCZ696 regimen were alive and had fewer hospitalizations than those given enalapril regimen1 -- Heart failure affects more than 600,000 Canadians18 and is responsible for 9 per...

2014-08-30 08:20:58

- Study showed significantly more HF-REF patients on LCZ696 regimen were alive, had fewer hospitalizations than those given enalapril regimen(1) EAST HANOVER, N.J., Aug. 30, 2014 /PRNewswire/ -- Today at the European Society of Cardiology congress and published simultaneously in the New England Journal of Medicine, Novartis revealed that its investigational heart failure medicine, LCZ696, was superior to ACE-inhibitor enalapril on key endpoints in the largest heart failure study ever...

2014-08-25 16:25:45

NASDAQ: CRME TSX: COM VANCOUVER, Aug. 25, 2014 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that its subsidiary, Correvio International Sàrl, has entered into an agreement with Eurolab Especialidades Medicinales de Eurofar S.R.L. to sell and distribute BRINAVESS(TM) (vernakalant intravenous) exclusively in Argentina. Under the terms of the agreement, Eurolab has agreed to specific annual commercial goals for BRINAVESS(TM). Financial details...

2014-08-19 08:29:39

DUBLIN, Aug. 19, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed positive topline results from RECLAIM-1 and -2, pivotal Phase III studies evaluating the potential for the investigational antibiotic, ceftazidime-avibactam as a treatment for adult hospitalized patients with complicated intra-abdominal infections. Logo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO Ceftazidime-avibactam consists of a cephalosporin (ceftazidime), an established treatment for...

2014-08-18 20:22:01

NEW YORK, Aug. 18, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Klebsiella Pneumoniae Infections-Pipeline Insights, 2014https://www.reportbuyer.com/product/2278616/-Klebsiella-Pneumoniae-Infections-Pipeline-Insights-2014.htmlSUMMARYDelveInsight's," Klebsiella Pneumoniae Infections-Pipeline Insights, 2014", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding...

2014-08-06 12:29:32

NASDAQ: CRME TSX: COM VANCOUVER, Aug. 6, 2014 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that William Hunter, M.D., President & CEO of Cardiome, will present an update on the company's progress at the Canaccord Genuity Growth Conference on August 13, 2014 at 2:00 p.m. EDT in Boston. A live webcast and a replay of the company's presentation will be available on the Cardiome corporate website at www.cardiome.com. About Cardiome Pharma...

2014-08-05 16:27:18

NASDAQ: CRME TSX: COM VANCOUVER, Aug. 5, 2014 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced submission of the BRINAVESS(TM) reimbursement dossier to Belgium's national compulsory health care and benefits insurance authority, The National Institute for Health and Disability Insurance (Institut National d'Assurance Maladie Invalidité or INAMI). "We are pleased to have submitted the application for BRINAVESS reimbursement and potentially could...

2014-08-05 12:32:08

NASDAQ: CRME, TSX: COM VANCOUVER, Aug. 5, 2014 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it will report financial results for the second quarter ended June 30, 2014 on the morning of Monday, August 11, 2014. Cardiome will hold a conference call and webcast at 8:00 a.m. Eastern (5:00 a.m. Pacific) on that day to discuss the results. To access the conference call, please dial 416-764-8688 or 888-390-0546 and use conference ID 04422550. The...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related